Elderly MG patients at high risk of treatment side effects
Elderly people with myasthenia gravis (MG) are at higher risk of experiencing side effects related to disease treatments,…
Marisa Horak joined Bionews in 2018 right after she completed her master’s degree in cellular and molecular pathology. She has dedicated her career to making scientific and medical information more accessible to people affected by rare and chronic disorders.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Elderly people with myasthenia gravis (MG) are at higher risk of experiencing side effects related to disease treatments,…
Soliris (eculizumab), already approved in Japan for adults with generalized myasthenia gravis (gMG), has now become the first…
The approval of Soliris (eculizumab) in the European Union now extends to children and adolescents, ages 6 to 17,…
A branch of the European Medicines Agency (EMA) recommended that the approval of Soliris (eculizumab) be expanded to include…
People with myasthenia gravis (MG) who are positive for antibodies against the acetylcholine receptor (AChR) — the most common…
Vyvgart (efgartigimod alfa-fcab) is now approved in Israel for the treatment of generalized myasthenia gravis (gMG), according to…
Repeated treatment with under-the-skin efgartigimod had a consistent effect in easing symptoms of…
People with generalized myasthenia gravis (gMG) treated with the experimental therapy rozanolixizumab in a clinical trial generally experienced…
Treatment with Vyvgart (efgartigimod alfa-fcab) over two years was found to safely and effectively ease symptoms of…
Treatment with the experimental therapy zilucoplan eased symptoms of generalized myasthenia gravis (gMG) across different subgroups of patients…
Get regular updates to your inbox.